罗小雨,马钦风

自身免疫性肝病（AILD）是一种病因不明、由免疫介导的复杂疾病，被认为是罕见疾病，但其发病率正在逐年增加，可进展为肝纤维化、肝硬化甚至肝衰竭。近年来我国AILD的病例报道越来越多，疾病负担也日益加重。该病的诊断常需结合临床表现、自身抗体、免疫球蛋白和肝脏组织学综合判断。AILD的早诊早治，动态随访，有助于改善疾病转归，甚至逆转早期肝硬化。

自身免疫性肝病；自身免疫性肝炎；原发性胆汁性胆管炎；原发性硬化性胆管炎

[1] Sucher,Elisabeth,Sucher,etal.AutoimmuneHepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies[J]. [2] Mack C L,Adams D,Assis D N,et al.Diagnosis and Management of Autoimmune Hepatitis in Adults and Children:2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases[J].Hepatology,2019,72(1). [3] Lindor K D,Bowlus C L,Boyer J,et al.Primary Biliary Cholangitis:2018 Practice Guidance from the American Association for the Study of Liver Diseases[J].Hepatology,2019. [4] Bowlus CL,ArrivéL,Bergquist A,et al.AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology.2022 Sep 9. [5] 苗琪,陈晓宇.自身免疫性肝病相关病理特征[J].胃肠病学,2018,23(5):6. [6] Mahmud N,Doshi SD,Forde KA,Khungar V.Transient elastography reliably estimates liver fibrosis in autoimmune hepatitis.Clinical and Experimental Hepatology.2019;5(3):244-249. [7] Yao M,Wang L,Leung P S C,et al.The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review[J].Clinical Reviews in Allergy&Immunology,2017. [8] YAO M,WANG L,WANG J,et al.Diagnostic value of se-rum golgi protein 73 for liver inflammation in patients with autoimmune hepatitis and primary biliary cholangitis[J].Dis Markers,2022,2022:4253566. [9] Lu C,Hou X,Li M,et al.Detection of AMA-M2 in human saliva:Potentials in diagnosis and monitoring of primary biliary cholangitis[J]. Scientific Reports,2017,7(1):796. [10] Yokoda RT,Carey EJ.Primary biliary cholangitis and primary Sclerosing cholangitis.Am J Gastroenterol.2019;114(10):1593-605. [11] Manne V,Kowdley KV.Obeticholic acid in primary biliary cholangitis:where we stand.Curr Opin Gastroenterol.2019;35(3):191-6. [12] Bowlus C L,Pockros P J,Andreas E.Kremer§,et al.Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis[J].Clinical gastroenterology and hepatology:the official clinical practice journal of the American Gastroenterological Association,2020(5):18. [13] Chen JL,Yang X,Zhang Q,Sun L,Liu Y,Zhu BB,et al.Effect of ursodeoxycholic acid with traditional Chinese medicine on biochemical response in patients with primary biliary cholangitis:a real-world cohort study.Chin J Hepatol.2018;26(12):909–15. [14] Dyson JK,Beuers U,Jones DEJ,et al.Primary sclerosing cholangitis[J].Lancet,2018,391(10139). [15] Mehta T I,Weissman S,Fung B M,et al.Global incidence,prevalence and features of primary sclerosing cholangitis:A systematic review and meta-analysis[J].Liver International. [16] Terziroli Beretta-Piccoli B,Mieli-Vergani G,Vergani D(2018)The clinical usage and definition of autoantibodies in immunemediated liver disease:a comprehensive overview.J Autoimmun95:144–158. [17] Tornai T,Tornai D,Sipeki N,et al.Loss of tolerance to gut immunity protein,glycoprotein 2(GP2)is associated with progressive disease course in primary sclerosing cholangitis[J].Rep,2018,8(1):399. [18] Tornai D,Papp M.Editorial:serologic antibodies in primary sclerosing cholangitis a tell-tale sign of compromised gut-liver immunity? Aliment Pharmacol Ther 2021;53:350-351. [19] Tornai D,Ven P L,Lakatos P L,et al.Serological biomarkers for management of primary sclerosing cholangitis[J].世界胃肠病学杂志:英文版,2022,28(21):11. [20] Davide R,Francesca S,Matteo R,et al.Utility of ElastPQ point-shear wave elastography in the work-up of patients with primary sclerosing cholangitis.[J].JHEP reports:innovation in hepatology,2023,5(11):100873-100873.

点击下载PDF